Peptide library › Cancer & imaging
Balixafortide
Also known as POL6326
Experimental CXCR4 blocker studied with chemotherapy for advanced breast cancer; its Phase 3 trial failed.
What people use it for
- Metastatic breast cancer (in trials)
What Balixafortide does in the body
A ring-shaped peptide that blocks CXCR4, a receptor tumours use to spread and to hide in protective environments.
Strength of evidence
Limited: early trials looked promising, but the Phase 3 FORTRESS trial with eribulin showed no benefit.
Look up the evidence
- Reviews on PubMed: Summaries of the published research
- Clinical trials on PubMed: Published studies in people
- ClinicalTrials.gov: Registered trials, past and ongoing
Live searches of official databases. New to the terms? See the glossary.
Reported side effects & risks
- Infusion reactions
- Low blood counts (with chemotherapy)
Who should avoid it or take extra care
- Not available outside research
Not a complete list. Check with a doctor or pharmacist about your own health and medicines.
Regulatory status
Investigational. Not approved by the FDA.
How it's taken
Route: Drip into a vein (in trials)
How long it lasts (half-life): Not well established in published data
Keep track of Balixafortide privately
Fiala is a free app for logging doses, tracking vials and setting reminders. No account, and everything you log stays on your phone.
Open Balixafortide in Fiala How to installMore in Cancer & imaging
- DegarelixMonthly hormone-blocking injection for advanced prostate cancer that lowers testosterone fast, without an initial flare.
- Lutetium Lu-177 dotatateTargeted radiation therapy that delivers radiation straight to neuroendocrine tumours.
- Lutetium Lu-177 vipivotide tetraxetanTargeted radiation therapy for advanced prostate cancer that carries the PSMA protein.
- Gallium Ga-68 dotatateRadioactive tracer used in PET scans to find neuroendocrine tumours.
- MotixafortideInjection that releases stem cells from the bone marrow so they can be collected before a transplant for multiple myeloma.
- LTX-315Experimental cancer-killing peptide injected directly into tumours to trigger an immune response.